Keywords
> MYOBASE > HEALTH > medicine > disease > disease by system > locomotor system diseases > neuromuscular disease > neuromuscular disease by clinic > neuromuscular junction disease
neuromuscular junction diseaseSee also: |
Documents disponibles dans cette catégorie (2147)
| Add the result to the basket | Make a suggestion | Refine your search
Extend search on down-posting(s)
Article
Balandina A ; Lecart S ; Dartevelle P ; Saoudi A ; Berrih-Aknin S | 2005Accès au résumé PubMed / to PubMed abstractArticle
Losen M ; Stassen MHW ; Martinez-Martinez P ; Machiels BM ; Duimel H ; Frederik PM ; Veldman H ; Wokke JHJ ; Spaans F ; Vincent A | 2005Accès au résumé PubMed / to PubMed abstractArticle
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Müller J ; Stucka R ; Neudecker S ; Zierz S ; Schmidt C ; Huebner A ; Lochmueller H ; Abicht A | 2005Communication n° 264 Objective : Congenital myasthenic syndromes (CMS) are caused by various genetic defects of presynaptic, synaptic and postsynaptic proteins. We report a postsynaptic CMS caused by two compound heterozygous mutations of the CH[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Poulas K ; Sideris S ; Tsiamalos P ; Kostelidou K ; Stergiou C ; Kordas G ; Tzartos SJ | 2005Communication n° 488 Muscle acetylcholine receptor (AChR), the autoantigen in myasthenia gravis, is difficult to be produced in large amounts as an intact molecule. We have successfully expressed soluble extracellular domains (ECDs) of ?, ?, ? a[...]Article
Fregonezi GAF ; Resqueti VR ; Guell R ; Pradas J ; Casan P | 2005Accès au résumé PubMed / to PubMed abstractArticle
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Brenner T ; Hamra-Amitay Y ; Sicsic C ; Berrih-Aknin S | 2005Communication n° 106 Myasthenia gravis is an antibody-mediated, autoimmune neuromuscular disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. The typical neuromuscular junction symptoms can be transiently allevi[...]Article
Yu H, Author ; Ishigaki K ; Shimahara T ; Bournaud R ; Le Poupon C ; Prado de Carvalho L ; Corringer PJ ; Fardeau M ; Koenig J ; Eymard B ; Hantaï D | 2005Communication n° 253 : Congenital myasthenic syndromes (CMS) are a group of rare genetic disorders that affect neuromuscular transmission. Most of the CMS are caused by mutations of the nicotinic acetylcholine receptor (nAChR) in skeletal muscl[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Sasso A ; Paucic-Kirincic E ; Lah-Tomulic K ; Gazdik M | 2005Communication n° 18 Congenital myasthenic syndrome with episodic apnea (CMS-EA) is a presynaptic disorder of neuromuscular junction. CMS-EA manifests at birth or early infancy. The clinical signs of the disease are ptosis, intermittent hypotonia[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Nouioua S ; Sifi Y ; Hecham N ; Ali Pacha L ; Richard P ; Grid D ; Hamri A ; Tazir M | 2005Communication n° 440 Introduction : Mutations in various genes expressed at the neuromuscular junction cause congenital myasthenic syndromes (CMS). Currently their classification is physiopathological, implicating 8 genes. Post-synaptic congenit[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Richard P ; Gaudon K ; Haddad H ; Koenig J ; Bauche S ; Grid D ; Gouider-Khouja N ; Mayer M ; Desnuelle C ; Pouget J ; Hentati F ; Eymard B ; Hantaï D | 2005Communication n° 235. Background: Congenital myasthenic syndromes (CMS) are hereditary disorders characterised by a defect in the neuromuscular transmission. Most cases showed recessive mode of inheritance and molecular analyses have shown that [...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Feferman T ; Cizeron-Clairac G ; Fuchs S ; Souroujon M ; Berrih-Aknin S | 2005Communication n° 448 Myasthenia Gravis (MG) is an autoimmune disease mediated by antibodies directed against the acetylcholine receptor (AChR), which are found in about 85% of patients. Autoimmune experimental MG (EAMG) can be induced in rats by[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Colomer J ; Müller JS ; Nascimiento A ; Vernet A ; Lochmuller H | 2005Communication n° 188 Introduction: The majority of postsynaptic congenital myasthenic syndromes (CMS) result from deficiency of acetylcholine receptors (AChR) at the endplate, due to mutations of the gene encoding the epsilon subunit of the AChR[...]Article
Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Nancy P ; Berrih-Aknin S | 2005Communication n° 505 Myasthenia gravis (MG) is an autoimmune disease associated with thymic hyperplasia, and is much more prevalent in women than in men. In this study we investigated potential changes in estrogen receptor (ER) expression in thy[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Frenkian-Cuvelier M ; Boneva N ; Clairac G ; Bidault J ; Berrih-Aknin S | 2005Communication n° 512 The Aquired Autoimmune Myasthenia Gravis (MG) is characterized by 3 immunological entities : seropositive MG (SPMG), seronegative MG (SNMG) and MuSK+. Despite the different immunological profile, all MG patients present the [...]Article
Schwartz DC ; Waclawik AJ ; Ringwala SN ; Robbins J | 2005Accès au résumé PubMed / to PubMed abstractArticle
Cette 6e édition a eu lieu sous la présidence conjointe des professeurs M. Fardeau et H. Sugita. Elle marque un tournant vers les thérapeutiques et a permis de nombreux échanges entre les deux communautés de chercheurs. Bref rappel histori[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Berrih-Aknin S ; Poëa-Guyon S ; Christadoss P ; Le Panse R ; Guyon T ; Bidault J ; Tzartos SJ | 2005Communication n° 590 Myasthenia gravis (MG) is an autoimmune disease associated with thymic pathologies, including hyperplasia. In this study we investigated the processes that may lead to thymic overexpression of the triggering antigen, the ace[...]Article
Fostieri E ; Tzartos SJ ; Berrih-Aknin S ; Beeson D ; Mamalaki A | 2005Accès au résumé PubMed / to PubMed abstractArticle
Barisic N ; Müller JS ; Paucic-Kirincic E ; Gazdik M ; Lah-Tomulic K ; Pertl A ; Sertic J ; Zurak N ; Lochmuller H ; Abicht A | 2005Accès au résumé PubMed / to PubMed abstractGuide
... Today, plasmapheresis is widely accepted for the treatment of myasthenia gravis, Lambert-Eaton syndrome, Guillain-Barré syndrome and chronic demyelinating polyneuropathy. Its effectiveness in other conditions, such as multiple sclerosis, pol[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Molenaar PC ; Ter Beek P ; Wintzen AR ; Verschuuren J ; Vincent A | 2005Communication n°369 The objective was to develop a mouse model for studying the pathophysiology of myasthenia gravis patients with auto-antibodies to MuSK, a tyrosine kinase receptor responsible for clustering of acetylcholine receptors (AChRs) [...]